Lamotrigine Tablet, Extended Release shortage
Lamotrigine Tablet, Extended Release is currently listed in shortage by the FDA. The FDA lists 6 affected products. This page was last refreshed from FDA data on Sep 23, 2026.
Par Pharma is permanently stopping its lamotrigine extended-release tablets. Other makers not reporting a shortage still list lamotrigine in orally disintegrating tablet form, but the extended-release tablet specifically has no available source reported right now.
Don’t stop or change your therapy on your own — talk with your prescriber about the plan that fits you, and ask your pharmacist what’s actually available (see options).
Do you take this drug? See the ‘What to do’ recommendation from Dr. Brian Staiger, PharmD →What’s in shortage — at a glance
These figures count only the manufacturers that reported this shortage to the FDA — not every company that makes Lamotrigine Tablet, Extended Release. Other makers that haven’t reported a problem are shown in the green card below.
Shortage timeline
-
Apr 29, 2026Currently in shortage6 of 6 products affected.
-
Apr 29, 2026First reported to the FDA6 products first listed.
Built from FDA posting and update dates. The end date FDA publishes is the posting/update date, not a true resolution date, so durations are approximate.
What exactly is on backorder — by manufacturer
Manufacturer: Par Health, Inc. 📞 800-828-9393 6 NDCS click to expand
| Status | NDC / product | Strength | Availability | Related information | Reason |
|---|---|---|---|---|---|
| To Be Discontinued | Lamotrigine, Tablet, Extended Release, 25 mg (NDC 49884-561-11) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Lamotrigine, Tablet, Extended Release, 250 mg (NDC 49884-604-11) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Lamotrigine, Tablet, Extended Release, 200 mg (NDC 49884-564-11) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Lamotrigine, Tablet, Extended Release, 50 mg (NDC 49884-562-11) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Lamotrigine, Tablet, Extended Release, 100 mg (NDC 49884-563-11) | — | — | Discontinuation of the manufacture of the drug | — |
| To Be Discontinued | Lamotrigine, Tablet, Extended Release, 300 mg (NDC 49884-605-11) | — | — | Discontinuation of the manufacture of the drug | — |
These rows are manufacturer reports to the FDA for Lamotrigine Tablet, Extended Release — they do not necessarily cover every manufacturer that makes this drug. A company appears here only if it told the FDA it has a supply problem, so other makers may still have stock. That’s the basis for the Where else can I get Lamotrigine Tablet, Extended Release? options further down this page.
Why is Lamotrigine Tablet, Extended Release in shortage?
Par Pharmaceutical is permanently stopping production of their extended-release lamotrigine tablets — and this affects every strength they made: 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg. They haven't shared a specific public reason for why they made this decision, just that manufacturing of these products is being discontinued for good.
It's worth knowing that this report only covers Par Pharmaceutical's versions of this medication. Other companies that make extended-release lamotrigine are not part of this particular report, and their status would be listed separately.
Based on the manufacturer-reported reason(s) and notes on file with the FDA for Lamotrigine Tablet, Extended Release, summarized in plain English by HelloPharmacist. A drug can be short for more than one reason, and the FDA updates these as manufacturers report changes.
What should I do if I take Lamotrigine Tablet, Extended Release?
Lamotrigine extended-release tablets are currently on the FDA shortage list. The one manufacturer on this record, Par Health, Inc., has reported that it is discontinuing this product, so I want to walk you through what that means and your next steps.
This affects every strength on the record — the 25 mg, 50 mg, 100 mg, 200 mg, 250 mg, and 300 mg extended-release tablets. All of these show no available source right now, and the reason listed is that the manufacturer is stopping production. Because this is a discontinuation rather than a temporary delay, the supply problem from this maker may be permanent, and a conversation with your prescriber is the right next step.
Please do not let this worry you into acting on your own. Here is how I would approach it:
- Do not stop, skip, or change your dose on your own — stopping suddenly can be harmful.
- Ask your pharmacy to check wholesalers and other manufacturers for extended-release lamotrigine.
- The same medicine, lamotrigine, is still made by other companies in different forms (for example Amneal and GlaxoSmithKline products); your pharmacy may be able to source one, though it may not be in local stock.
- Ask your prescriber or pharmacist which option best matches your current dose.
Manufacturer contact numbers are listed on this page for reference, though pharmacies usually make these calls. This is national, manufacturer-reported information and may not match your local pharmacy's stock.
- Don’t stop or change the medication on your own — talk to your prescriber first.
- If this is part of an ongoing or essential regimen (for example HIV treatment or prevention, seizure, heart, transplant, diabetes or mental-health medicines), do not skip or ration doses — contact your pharmacist or prescriber right away to arrange continued supply before you run out.
- Ask your pharmacy to check other manufacturers, strengths, package sizes, and nearby stores.
- Ask your prescriber whether a different strength, formulation, or the brand/generic version is appropriate.
Uses, dosing, side effects, prices, and the complete FDA label — written in plain English and pharmacist-reviewed.
Where else can I get Lamotrigine Tablet, Extended Release?
FDA shortages are manufacturer-reported — a company only shows up on the shortage list if it told the FDA it has a supply problem, so not every maker of Lamotrigine Tablet, Extended Release is necessarily short. Below we pull together the other still-marketed options that are not reported in shortage: the same medicine from manufacturers that haven’t reported a problem, and alternative dosage forms. These may still be out of stock at your pharmacy, and only your prescriber or pharmacist can decide what’s right for you.
Same medicine, other manufacturers (not reported short)
Same active ingredient, dosage form & route as the shortage (matched on the FDB HICL ingredient code), from makers that have not filed a shortage with the FDA:
| Product | Strength | Form / route | Manufacturer | NDC |
|---|---|---|---|---|
| Lamotrigine | LAMOTRIGINE 25 mg/1 | Tablet, Orally Disintegrating · Oral | Amneal Pharmaceuticals of New York LLC | 00115-1526-08 |
| Lamotrigine | LAMOTRIGINE 50 mg/1 | Tablet, Orally Disintegrating · Oral | Amneal Pharmaceuticals of New York LLC | 00115-1527-08 |
| Lamotrigine | LAMOTRIGINE 100 mg/1 | Tablet, Orally Disintegrating · Oral | Amneal Pharmaceuticals of New York LLC | 00115-1528-08 |
| Lamotrigine | LAMOTRIGINE 200 mg/1 | Tablet, Orally Disintegrating · Oral | Amneal Pharmaceuticals of New York LLC | 00115-1529-08 |
| Lamictal | LAMOTRIGINE 5 mg/1 | Tablet, For Suspension · Oral | GlaxoSmithKline LLC | 00173-0526-00 |
| Lamictal | LAMOTRIGINE 25 mg/1 | Tablet, For Suspension · Oral | GlaxoSmithKline LLC | 00173-0527-00 |
| Lamictal | LAMOTRIGINE 25 mg/1 | Tablet · Oral | GlaxoSmithKline LLC | 00173-0633-02 |
| Lamictal | LAMOTRIGINE 100 mg/1 | Tablet · Oral | GlaxoSmithKline LLC | 00173-0642-55 |
| Lamictal | LAMOTRIGINE 150 mg/1 | Tablet · Oral | GlaxoSmithKline LLC | 00173-0643-60 |
| Lamictal | LAMOTRIGINE 200 mg/1 | Tablet · Oral | GlaxoSmithKline LLC | 00173-0644-60 |
| Lamictal | LAMOTRIGINE 2 mg/1 | Tablet, For Suspension · Oral | GlaxoSmithKline LLC | 00173-0699-00 |
| Lamictal Xr | LAMOTRIGINE 25 mg/1 | Tablet, Film Coated, Extended Release · Oral | GlaxoSmithKline LLC | 00173-0754-00 |
Alternative dosage forms of Lamotrigine Tablet, Extended Release
A different form of the same drug (for example a solution when capsules are short). A form change is a clinical decision — ask your prescriber:
Therapeutic equivalents & pricing 30 productsclick to expand
Orange Book–rated equivalents of the affected strengths, with the latest NADAC price (a federal retail-acquisition benchmark, not your copay) and an evidence-based availability label. Cheapest first.
| Product | Manufacturer | Package | NADAC $/unit | AB rating | Availability |
|---|---|---|---|---|---|
| Lamotrigine 25 mg | Actavis | 30 tablets | $0.254 | AB | Discontinued |
| Lamotrigine 25 mg | NorthStar | 30 tablets | $0.254 | AB | Availability likely |
| lamotrigine 25 mg | Camber | 30 tablets | $0.254 | AB | Availability likely |
| Lamotrigine Extended Release 25 mg | Par | 30 tablets | $0.254 | — | Availability likely |
| Lamotrigine 25 mg | Amneal | 30 tablets | $0.254 | AB | Availability likely |
| Lamotrigine 200 mg | Actavis | 30 tablets | $0.618 | AB | Availability likely |
| Lamotrigine 200 mg | NorthStar | 30 tablets | $0.618 | AB | Availability likely |
| lamotrigine 200 mg | Camber | 30 tablets | $0.618 | AB | Availability likely |
| Lamotrigine 200 mg | Amneal | 30 tablets | $0.618 | AB | Availability likely |
| Lamotrigine Extended Release 200 mg | Par | 30 tablets | $0.775 | — | Discontinued |
| Lamotrigine 250 mg | Actavis | 30 tablets | $1.253 | AB | Availability likely |
| Lamotrigine 250 mg | NorthStar | 30 tablets | $1.253 | AB | Availability likely |
| lamotrigine 250 mg | Camber | 30 tablets | $1.253 | AB | Availability likely |
| Lamotrigine Extended Release 250 mg | Par | 30 tablets | $1.253 | — | Availability likely |
| Lamotrigine 250 mg | Amneal | 30 tablets | $1.253 | AB | Availability likely |
| Lamictal Xr 25 mg | GlaxoSmithKline | 30 tablets | $14.204 | AB | Availability likely |
| Lamictal Xr 200 mg | GlaxoSmithKline | 30 tablets | $32.331 | AB | Availability likely |
| Lamictal Xr 250 mg | GlaxoSmithKline | 30 tablets | $44.163 | AB | Availability likely |
| Lamotrigine 25 mg | Torrent | 100 tablets | — | AB | FDA listed |
| Lamotrigine 25 mg | AvKARE | 30 tablets | — | AB | FDA listed |
| Lamotrigine 25 mg | Dr.Reddy's | 500 tablets | — | AB | FDA listed |
| Lamotrigine 25 mg | Zydus | 500 tablets | — | AB | FDA listed |
| lamotrigine 25 mg | Yiling | 30 tablets | — | AB | FDA listed |
| Lamotrigine 25 mg | Zydus | 30 tablets | — | AB | FDA listed |
| Lamotrigine 25 mg | Bryant | 30 tablets | — | AB | FDA listed |
| Lamotrigine Extended-Release 250 mg | Par | 30 tablets | — | AB | FDA listed |
| Lamotrigine 250 mg | AvKARE | 30 tablets | — | AB | FDA listed |
| Lamotrigine 250 mg | Alembic | 30 tablets | — | AB | FDA listed |
| Lamotrigine 250 mg | Dr.Reddy's | 500 tablets | — | AB | FDA listed |
| Lamotrigine 250 mg | Alembic | 30 tablets | — | AB | FDA listed |
Equivalents share the same ingredient, strength, dosage form and route; an AB rating means the FDA considers them substitutable. NADAC is a national retail-pharmacy acquisition benchmark from CMS — not what you pay. Availability is inferred from recent pricing, not a stock check.
Other drugs in the same treatment class
These are different medicines — not other versions of Lamotrigine Tablet, Extended Release — that fall in the same broad treatment class (anticonvulsants) . They are not automatic substitutes: they can differ in how they work, dosing, effectiveness, side effects and what they’re approved to treat. Do not switch on your own. This list is for information only — ask your prescriber or pharmacist whether any of them is appropriate for you.
Identity & classification
Where does this data come from?
Other neurology shortages
Lamotrigine Tablet, Extended Release shortage FAQs
Is Lamotrigine Tablet, Extended Release in shortage?
Which products are affected?
When will Lamotrigine Tablet, Extended Release be available again?
Can I still get Lamotrigine Tablet, Extended Release somewhere?
What should I do if I take Lamotrigine Tablet, Extended Release?
Still have a question about the Lamotrigine Tablet, Extended Release shortage?
Ask a pharmacist about this shortage →View Lamotrigine Tablet, Extended Release on the FDA drug-shortage database →
Where does this data come from?
/drug/shortages) — drug, manufacturer & contact, NDC/product, status, availability, reason, therapeutic category and posting/update dates. Current / To Be Discontinued = active; Resolved is kept for history. The Supply-Risk rating is assessed per active ingredient and adds the FDA NDC Directory (still-marketed manufacturers by ingredient & form); same-medicine and equivalent products use First Databank classification + CMS NADAC pricing; Medicaid use + most-affected states come from CMS Medicaid State Drug Utilization Data. Reference only — confirm current status with the manufacturer or FDA before acting on it.